Our group has conducted research on various aspects of obesity and its impact on IBD including safety of bariatric surgery in IBD and its impact on disease activity in IBD. We have also assessed non-alcoholic fatty liver disease (NAFLD) in Crohn’s disease, including its prevalence, risk factors for NAFLD, interactions with Crohn’s disease activity and medical therapy used in Crohn’s disease using proton density fat fraction mapping during MRE for disease activity assessment. Ongoing work is look at the impact of visceral adipose tissue on responses to advanced therapies, risk of ASCVD events in patients with IBD. We are now funded by the Helmsley Charitable Trust to study the effectiveness and safety of GLP1 receptor agonists on Crohn’s disease in collaboration with Mt. Sinai, NYC and Cedar’s Sinai, Los Angeles.
- McHenry SA, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, Salter A, Browning JD, Flores A, Davidson NO, Fowler KJ, Ciorba MA, Deepak P. Crohn’s Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat FractionMapping. Clin. Gastroenterol. Hepatol. 2019 Dec;17(13):2816-2818. PMID: 30876963
- Alayo QA, Loftus EV Jr, Yarur A, Alvarado D, Ciorba MA, de Las Fuentes L, Deepak P. Inflammatory Bowel Disease Is Associated With an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank. Clin Gastroenterol Hepatol. 2023 Mar;21(3):761-770. PMID: 36075499
- Yarur AJ, Bruss A, Moosreiner A, Beniwal-Patel P, Nunez L, Berens B, Colombel JF, Targan SR, Fox C, Melmed GY, Abreu MT, Deepak P. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023 Oct;165(4):963-975. PMID: 37499955
- Anderson SR, Ayoub M, Coats S, McHenry S, Tan T, Deepak P. Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease. Am J Gastroenterol. 2024 Nov 14. PMID: 39717004
- Mattay SS, Zamani M, Saturno D, Loftus EV Jr, Ciorba MA, Yarur A, Singh S, Deepak P. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis. Clin Gastroenterol Hepatol. 2024 May;22(5):961-970.e12. PMID: 37821035